Department of Obstetrics, Gynecology, and Women's Health, University of Hawaii John A. Burns School of Medicine, Honolulu, HI, USA.
Department of Obstetrics, Gynecology, and Women's Health, University of Hawaii John A. Burns School of Medicine, Honolulu, HI, USA.
Contraception. 2022 Jun;110:71-75. doi: 10.1016/j.contraception.2022.03.003. Epub 2022 Mar 11.
We aimed to characterize the current pain experience of patients completing an evidence-based mifepristone-misoprostol medication abortion regimen using real-time pain scores.
We collected real-time data on pain experienced by 54 women undergoing medication abortion using an evidence-based regimen of 200 mg mifepristone and 800 mcg buccal misoprostol. These women were enrolled in the placebo arm of a study on the effect of pregabalin for pain during medication abortion. All participants were dispensed ibuprofen and oxycodone/acetaminophen for analgesia. We assessed maximum pain experienced by participants on an 11-point numerical rating scale (NRS), duration of pain, and analgesic usage. Data was collected through electronic surveys sent via text message link at 6 specified points over 72 hours.
Of the 54 women randomized to the placebo group, 2 were lost to follow-up. Participants experienced a mean maximum pain score of 5.5 ± 2.2. The mean time to maximum pain was 3.7 ± 2.4 hours after misoprostol. By hour 12 after misoprostol, 60.8% of participants reported no pain, which increased to 76.9% at 24 hours and 82.0% at 72 hours. Participants reported median ibuprofen usage of 2 800 mg tablets and median oxycodone/acetaminophen usage of one-half of a 5/325mg tablet. Approximately 12.0% of participants reported taking zero ibuprofen tablets, and 50.0% reported no opioid usage during the study period.
Our real-time data collection demonstrated lower mean maximum experienced pain scores and shorter duration of pain than previously reported for medication abortion. Analgesic use was lower than previously described.
This updated characterization of pain experienced during an evidence-based medication abortion regimen may allow for better pain-related counseling, tailoring of opioid prescription practices, and improvement in patient satisfaction.
通过实时疼痛评分,描述正在接受基于证据的米非司酮-米索前列醇药物流产方案的患者的当前疼痛体验。
我们收集了 54 名接受基于证据的 200 毫克米非司酮和 800 微克口腔米索前列醇药物流产方案的女性的实时疼痛数据。这些女性参加了一项关于普瑞巴林在药物流产期间止痛效果的研究的安慰剂组。所有参与者均开具布洛芬和羟考酮/对乙酰氨基酚用于镇痛。我们使用 11 点数字评分量表(NRS)评估参与者经历的最大疼痛、疼痛持续时间和镇痛药使用情况。通过电子问卷在 72 小时内的 6 个特定时间点通过短信链接收集数据。
在随机分配到安慰剂组的 54 名女性中,有 2 名失访。参与者经历的平均最大疼痛评分为 5.5 ± 2.2。服用米索前列醇后达到最大疼痛的平均时间为 3.7 ± 2.4 小时。在服用米索前列醇后 12 小时,60.8%的参与者报告无疼痛,24 小时时增加到 76.9%,72 小时时增加到 82.0%。参与者报告中位数布洛芬使用量为 2 800 毫克片剂,中位数羟考酮/对乙酰氨基酚使用量为半片 5/325 毫克片剂。约 12.0%的参与者报告没有服用任何布洛芬片剂,50.0%的参与者在研究期间没有使用阿片类药物。
我们的实时数据收集显示,与先前报道的药物流产相比,平均最大疼痛评分和疼痛持续时间较低。镇痛药的使用低于先前的描述。
对基于证据的药物流产方案中疼痛体验的这种更新描述,可能有助于更好地进行与疼痛相关的咨询、调整阿片类药物处方实践,并提高患者满意度。